Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics
Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2019-03, Vol.38 (3), p.593-600 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 600 |
|---|---|
| container_issue | 3 |
| container_start_page | 593 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 38 |
| creator | Ohashi, Kengo Matsuoka, Tomoko Shinoda, Yasutaka Mori, Takayuki Yoshida, Shinya Yoshimura, Tomoaki Sugiyama, Tadashi |
| description | Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From January 2016 to December 2016, PAF was performed in patients using specific antibiotics (period 1) and from January 2017 to December 2017, PAF was performed in patients using whole injectable antibiotics (period 2). PAF was implemented for 5 days every week by pharmacists involved in infectious diseases chemotherapy. In total, 11,571 and 11,103 patients used antibiotic injections during periods 1 and 2, respectively. No significant difference in mortality within 30 days from the initial use of injection antibiotics was observed. The average duration of hospitalisation was significantly shorter during period 2 among patients using antibiotics; however, this was not significantly different from that of patients not receiving antibiotics. The average duration of therapy for intravenous antibiotics was significantly shorter during period 2 than during period 1. The ratio of methicillin-resistant
Staphylococcus aureus
(MRSA) to
S. aureus
was significantly low during period 2. The duration of intravenous antibiotic therapy for
Escherichia coli
bacteraemia during period 2 decreased significantly. De-escalation and appropriate antimicrobial treatment rates at specific doses during period 2 increased significantly. Expansion of patients eligible for PAF from patients using specific antibiotics to patients using whole injectable antibiotics shortened hospital stays, suppressed drug resistance, and promoted the appropriate use of antibiotics. |
| doi_str_mv | 10.1007/s10096-018-03465-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179420338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179420338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-d064828649dfd1bc1dd2b174afe78f742b51e7038f3f1d258fe24fe94b842ae53</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhBVggS2y6CfVfYmeJRhSQKrFp15FjX3c8JHaInbb0yXg8HGb4EYtubEv3O-dY9yD0mpJ3lBB5nsrZNhWhqiJcNHX18ARtqOB1JbjkT9GGtFxUrWT8BL1IaU-KSEn5HJ1w0ihSN_UG_dgOPnijBxyXbOIIODo87fQ8auNTrgaweJpjmsBkfwtYL9ZnfOfzDvuQYb6FkH0MWAeLHYDttfmKtSsTDPeTDmkdujmOeNLZFzjhJflwg1dH77wpyux7H7M3CeeI8y4mODJ3uzhAydmXcN2X5z_sS_TM6SHBq-N9iq4vPlxtP1WXXz5-3r6_rAyXda4saYRiqhGtdZb2hlrLeiqFdiCVk4L1NQVJuHLcUctq5YAJB63olWAaan6Kzg6-ZQvfFki5G30yMAw6QFxSx6hsBSOcq4K-_Q_dx2UO5XcrVXbfNnSl2IEyZa1pBtdNsx_1_L2jpFt77Q69dqXX7lev3UMRvTlaL_0I9o_kd5EF4AcglVG4gflv9iO2PwE417QA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2170789618</pqid></control><display><type>article</type><title>Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics</title><source>Springer Nature - Complete Springer Journals</source><creator>Ohashi, Kengo ; Matsuoka, Tomoko ; Shinoda, Yasutaka ; Mori, Takayuki ; Yoshida, Shinya ; Yoshimura, Tomoaki ; Sugiyama, Tadashi</creator><creatorcontrib>Ohashi, Kengo ; Matsuoka, Tomoko ; Shinoda, Yasutaka ; Mori, Takayuki ; Yoshida, Shinya ; Yoshimura, Tomoaki ; Sugiyama, Tadashi</creatorcontrib><description>Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From January 2016 to December 2016, PAF was performed in patients using specific antibiotics (period 1) and from January 2017 to December 2017, PAF was performed in patients using whole injectable antibiotics (period 2). PAF was implemented for 5 days every week by pharmacists involved in infectious diseases chemotherapy. In total, 11,571 and 11,103 patients used antibiotic injections during periods 1 and 2, respectively. No significant difference in mortality within 30 days from the initial use of injection antibiotics was observed. The average duration of hospitalisation was significantly shorter during period 2 among patients using antibiotics; however, this was not significantly different from that of patients not receiving antibiotics. The average duration of therapy for intravenous antibiotics was significantly shorter during period 2 than during period 1. The ratio of methicillin-resistant
Staphylococcus aureus
(MRSA) to
S. aureus
was significantly low during period 2. The duration of intravenous antibiotic therapy for
Escherichia coli
bacteraemia during period 2 decreased significantly. De-escalation and appropriate antimicrobial treatment rates at specific doses during period 2 increased significantly. Expansion of patients eligible for PAF from patients using specific antibiotics to patients using whole injectable antibiotics shortened hospital stays, suppressed drug resistance, and promoted the appropriate use of antibiotics.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-018-03465-z</identifier><identifier>PMID: 30680565</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibiotics ; Antiinfectives and antibacterials ; Antimicrobial agents ; Bacteremia ; Biomedical and Life Sciences ; Biomedicine ; Chemotherapy ; Drug resistance ; E coli ; Feedback ; Infectious diseases ; Internal Medicine ; Intravenous administration ; Medical Microbiology ; Methicillin ; Original Article ; Patients ; Public health ; Staphylococcus aureus ; Staphylococcus infections</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2019-03, Vol.38 (3), p.593-600</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>European Journal of Clinical Microbiology & Infectious Diseases is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-d064828649dfd1bc1dd2b174afe78f742b51e7038f3f1d258fe24fe94b842ae53</citedby><cites>FETCH-LOGICAL-c375t-d064828649dfd1bc1dd2b174afe78f742b51e7038f3f1d258fe24fe94b842ae53</cites><orcidid>0000-0002-7105-7982</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-018-03465-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-018-03465-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27915,27916,41479,42548,51310</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30680565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ohashi, Kengo</creatorcontrib><creatorcontrib>Matsuoka, Tomoko</creatorcontrib><creatorcontrib>Shinoda, Yasutaka</creatorcontrib><creatorcontrib>Mori, Takayuki</creatorcontrib><creatorcontrib>Yoshida, Shinya</creatorcontrib><creatorcontrib>Yoshimura, Tomoaki</creatorcontrib><creatorcontrib>Sugiyama, Tadashi</creatorcontrib><title>Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From January 2016 to December 2016, PAF was performed in patients using specific antibiotics (period 1) and from January 2017 to December 2017, PAF was performed in patients using whole injectable antibiotics (period 2). PAF was implemented for 5 days every week by pharmacists involved in infectious diseases chemotherapy. In total, 11,571 and 11,103 patients used antibiotic injections during periods 1 and 2, respectively. No significant difference in mortality within 30 days from the initial use of injection antibiotics was observed. The average duration of hospitalisation was significantly shorter during period 2 among patients using antibiotics; however, this was not significantly different from that of patients not receiving antibiotics. The average duration of therapy for intravenous antibiotics was significantly shorter during period 2 than during period 1. The ratio of methicillin-resistant
Staphylococcus aureus
(MRSA) to
S. aureus
was significantly low during period 2. The duration of intravenous antibiotic therapy for
Escherichia coli
bacteraemia during period 2 decreased significantly. De-escalation and appropriate antimicrobial treatment rates at specific doses during period 2 increased significantly. Expansion of patients eligible for PAF from patients using specific antibiotics to patients using whole injectable antibiotics shortened hospital stays, suppressed drug resistance, and promoted the appropriate use of antibiotics.</description><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Antimicrobial agents</subject><subject>Bacteremia</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Chemotherapy</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Feedback</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Intravenous administration</subject><subject>Medical Microbiology</subject><subject>Methicillin</subject><subject>Original Article</subject><subject>Patients</subject><subject>Public health</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus infections</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1u1DAUhS0EokPhBVggS2y6CfVfYmeJRhSQKrFp15FjX3c8JHaInbb0yXg8HGb4EYtubEv3O-dY9yD0mpJ3lBB5nsrZNhWhqiJcNHX18ARtqOB1JbjkT9GGtFxUrWT8BL1IaU-KSEn5HJ1w0ihSN_UG_dgOPnijBxyXbOIIODo87fQ8auNTrgaweJpjmsBkfwtYL9ZnfOfzDvuQYb6FkH0MWAeLHYDttfmKtSsTDPeTDmkdujmOeNLZFzjhJflwg1dH77wpyux7H7M3CeeI8y4mODJ3uzhAydmXcN2X5z_sS_TM6SHBq-N9iq4vPlxtP1WXXz5-3r6_rAyXda4saYRiqhGtdZb2hlrLeiqFdiCVk4L1NQVJuHLcUctq5YAJB63olWAaan6Kzg6-ZQvfFki5G30yMAw6QFxSx6hsBSOcq4K-_Q_dx2UO5XcrVXbfNnSl2IEyZa1pBtdNsx_1_L2jpFt77Q69dqXX7lev3UMRvTlaL_0I9o_kd5EF4AcglVG4gflv9iO2PwE417QA</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Ohashi, Kengo</creator><creator>Matsuoka, Tomoko</creator><creator>Shinoda, Yasutaka</creator><creator>Mori, Takayuki</creator><creator>Yoshida, Shinya</creator><creator>Yoshimura, Tomoaki</creator><creator>Sugiyama, Tadashi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7105-7982</orcidid></search><sort><creationdate>20190301</creationdate><title>Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics</title><author>Ohashi, Kengo ; Matsuoka, Tomoko ; Shinoda, Yasutaka ; Mori, Takayuki ; Yoshida, Shinya ; Yoshimura, Tomoaki ; Sugiyama, Tadashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-d064828649dfd1bc1dd2b174afe78f742b51e7038f3f1d258fe24fe94b842ae53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Antimicrobial agents</topic><topic>Bacteremia</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Chemotherapy</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Feedback</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Intravenous administration</topic><topic>Medical Microbiology</topic><topic>Methicillin</topic><topic>Original Article</topic><topic>Patients</topic><topic>Public health</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ohashi, Kengo</creatorcontrib><creatorcontrib>Matsuoka, Tomoko</creatorcontrib><creatorcontrib>Shinoda, Yasutaka</creatorcontrib><creatorcontrib>Mori, Takayuki</creatorcontrib><creatorcontrib>Yoshida, Shinya</creatorcontrib><creatorcontrib>Yoshimura, Tomoaki</creatorcontrib><creatorcontrib>Sugiyama, Tadashi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ohashi, Kengo</au><au>Matsuoka, Tomoko</au><au>Shinoda, Yasutaka</au><au>Mori, Takayuki</au><au>Yoshida, Shinya</au><au>Yoshimura, Tomoaki</au><au>Sugiyama, Tadashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>38</volume><issue>3</issue><spage>593</spage><epage>600</epage><pages>593-600</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From January 2016 to December 2016, PAF was performed in patients using specific antibiotics (period 1) and from January 2017 to December 2017, PAF was performed in patients using whole injectable antibiotics (period 2). PAF was implemented for 5 days every week by pharmacists involved in infectious diseases chemotherapy. In total, 11,571 and 11,103 patients used antibiotic injections during periods 1 and 2, respectively. No significant difference in mortality within 30 days from the initial use of injection antibiotics was observed. The average duration of hospitalisation was significantly shorter during period 2 among patients using antibiotics; however, this was not significantly different from that of patients not receiving antibiotics. The average duration of therapy for intravenous antibiotics was significantly shorter during period 2 than during period 1. The ratio of methicillin-resistant
Staphylococcus aureus
(MRSA) to
S. aureus
was significantly low during period 2. The duration of intravenous antibiotic therapy for
Escherichia coli
bacteraemia during period 2 decreased significantly. De-escalation and appropriate antimicrobial treatment rates at specific doses during period 2 increased significantly. Expansion of patients eligible for PAF from patients using specific antibiotics to patients using whole injectable antibiotics shortened hospital stays, suppressed drug resistance, and promoted the appropriate use of antibiotics.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30680565</pmid><doi>10.1007/s10096-018-03465-z</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7105-7982</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2019-03, Vol.38 (3), p.593-600 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179420338 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Antibiotics Antiinfectives and antibacterials Antimicrobial agents Bacteremia Biomedical and Life Sciences Biomedicine Chemotherapy Drug resistance E coli Feedback Infectious diseases Internal Medicine Intravenous administration Medical Microbiology Methicillin Original Article Patients Public health Staphylococcus aureus Staphylococcus infections |
| title | Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T03%3A20%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20of%20pharmacist-led%20prospective%20audit%20with%20intervention%20and%20feedback%20after%20expansion%20from%20patients%20using%20specific%20antibiotics%20to%20those%20using%20whole%20injectable%20antibiotics&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Ohashi,%20Kengo&rft.date=2019-03-01&rft.volume=38&rft.issue=3&rft.spage=593&rft.epage=600&rft.pages=593-600&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-018-03465-z&rft_dat=%3Cproquest_cross%3E2179420338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2170789618&rft_id=info:pmid/30680565&rfr_iscdi=true |